Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check3 days agoChange DetectedNew navigation/help sections were added to help users find joining information, contact details, how to read a study record, common questions, and how to join a study. The 'Intervention / Treatment' label was normalized to 'Intervention/Treatment' and the revision tag updated to v3.6.0.SummaryDifference0.4%

- Check11 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5, indicating a new page build. The change does not alter the study details, eligibility, or results presented on the page.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was deleted, reflecting an updated version tag for the record rather than substantive content changes.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page’s footer revision label was updated from **v3.5.0** to **v3.5.3**.SummaryDifference0.0%

- Check89 days agoChange DetectedAdded Hepatocellular carcinoma to the list of conditions and updated the study version from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check103 days agoChange DetectedThe page revision tag was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.